Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioma 3Recurrence 2Glioblastoma 2Astrocytoma 2Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × IL13-PE38 × Clear all
NCT00024570 2014-11-14

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Completed
60 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

NCT00378235 2014-11-13

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Withdrawn
CNS

Glioma, Recurrence

NCT00041587 2011-06-06

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Completed
80 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡